Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) closed at $52.47 in the last session, up 0.04% from day before closing price of $52.45. In other words, the price has increased by $0.04 from its previous closing price. On the day, 2.45 million shares were traded. BMRN stock price reached its highest trading level at $52.805 during the session, while it also had its lowest trading level at $51.565.
Ratios:
We take a closer look at BMRN’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.04 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.50. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 5.56. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on September 08, 2025, initiated with a Neutral rating and assigned the stock a target price of $60.
On September 03, 2025, Raymond James started tracking the stock assigning a Outperform rating and target price of $85.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 20 ’25 when Burkhart Erin sold 1,786 shares for $59.31 per share. The transaction valued at 105,928 led to the insider holds 14,173 shares of the business.
Burkhart Erin bought 1,786 shares of BMRN for $105,928 on May 20 ’25. On May 02 ’25, another insider, Hubbard Cristin, who serves as the EVP, Chief Commercial Officer of the company, sold 273 shares for $64.92 each. As a result, the insider received 17,723 and left with 32,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 10075006976 and an Enterprise Value of 9246746624. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.54, and their Forward P/E ratio for the next fiscal year is 11.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.31 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 3.018 whereas that against EBITDA is 9.681.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.33, which has changed by -0.25213796 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $73.51, while it has fallen to a 52-week low of $51.78. The 50-Day Moving Average of the stock is -6.46%, while the 200-Day Moving Average is calculated to be -13.66%.
Shares Statistics:
According to the various share statistics, BMRN traded on average about 2.13M shares per day over the past 3-months and 2322430 shares per day over the past 10 days. A total of 192.00M shares are outstanding, with a floating share count of 189.12M. Insiders hold about 1.51% of the company’s shares, while institutions hold 97.58% stake in the company. Shares short for BMRN as of 1759190400 were 7155141 with a Short Ratio of 3.37, compared to 1756425600 on 5956363. Therefore, it implies a Short% of Shares Outstanding of 7155141 and a Short% of Float of 4.78.
Earnings Estimates
As of right now, 18.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.01, with high estimates of $1.36 and low estimates of $0.83.
Analysts are recommending an EPS of between $4.81 and $2.71 for the fiscal current year, implying an average EPS of $4.07. EPS for the following year is $5.4, with 20.0 analysts recommending between $6.19 and $4.57.
Revenue Estimates
According to 21 analysts, . The current quarter’s revenue is expected to be $784.46M. It ranges from a high estimate of $822M to a low estimate of $725M. As of . The current estimate, Biomarin Pharmaceutical Inc’s year-ago sales were $745.74MFor the next quarter, 21 analysts are estimating revenue of $818.14M. There is a high estimate of $838.6M for the next quarter, whereas the lowest estimate is $787M.
A total of 25 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $3.21B, while the lowest revenue estimate was $3.08B, resulting in an average revenue estimate of $3.17B. In the same quarter a year ago, actual revenue was $2.85BBased on 24 analysts’ estimates, the company’s revenue will be $3.45B in the next fiscal year. The high estimate is $3.7B and the low estimate is $3.2B.
